• Publications
  • Influence
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
The ProTide 6f is now in clinical development with encouraging efficacy signals in a Phase I/II study, which strongly supports the ProTid approach to generate promising new anticancer agents.
PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer: prognostic significance.
It is shown that PLGF isoforms PLGF-1 and PGF-2 and indeed their receptor neuopilin, have an aberrant pattern of expression and that high levels of the placenta growth factor and neuropilin are linked to a poor prognosis.
The Era of Multigene Panels Comes? The Clinical Utility of Oncotype DX and MammaPrint
A review of the studies on these multigene panels in predicting clinical outcome and treatment response in breast cancer and their application to breast cancer.
Novel potential anticancer naphthyl phosphoramidates of BVdU: separation of diastereoisomers and assignment of the absolute configuration of the phosphorus center.
We have previously reported our SAR optimization of the anticancer agent thymectacin. Tuning of the parent ProTide structure initially involved the amino acid and, subsequently, the aromatic masking
Expression of breast cancer specific gene-1 (BCSG-1/gamma-synuclein) is associated with tumour grade but not with clinical outcome of patients with breast cancer.
BCSG-1 is increased in breast tumour cells, is negatively associated with tumour grade and significantly correlates with levels of transglutaminase-3.
Long-term exposure to low doses of fresh and aged zinc oxide nanoparticles causes cell malignant progression enhanced by a tyrosine phosphatase SHP2 gain-of-function mutation
Compared to fresh zinc oxide NPs, aged zinc oxide NPs induce higher levels of ROS and DNA double strand breaks, as well as more pronounced cell malignant progression in the tyrosine phosphatase SHP2